Trustees of Tufts College, doing business as Tufts University School of Medicine, received a $453,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding will support research to define the potential of gene therapy to correct motor disabilities associated with CTNNB1 syndrome, a rare genetic disorder characterized by intellectual disabilities, developmental delays, and motor impairments. The work will utilize in vivo mouse models and in vitro human cell cultures to test whether gene therapy can increase CTNNB1 (β-catenin) levels and significantly improve the motor phenotypes observed in these CTNNB1 heterozygous models. This critical proof-of-concept research aims to inform the development of therapeutic strategies that could provide life-altering benefits for children affected by CTNNB1 syndrome.